TheraRadar
Landscape → Oncology

Hepatocellular Carcinoma Clinical Trial Landscape

Data updated: May 20, 2026

1,396 clinical trials tracked since 2008

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, primarily affecting individuals with underlying liver diseases such as cirrhosis. As a significant area of oncological research, the clinical trial landscape for HCC is robust, with 1,383 trials registered since 2008. Currently, 616 trials are actively recruiting, enrolling, or active but not recruiting patients. The majority of active trials are in Phase 2 (390 trials), followed by Phase 1 (214 trials), suggesting a strong focus on early-stage drug development and investigation of novel therapeutic approaches. Phase 3 trials account for 91 active studies, while Phase 4 trials represent 24 active studies. AstraZeneca leads industry sponsorship with 12 active trials, followed by Roche and Akeso, each with 6 active trials. Shanghai Henlius Biotech and AbbVie are also notable sponsors, each with 4 active trials. The higher number of Phase 2 trials compared to Phase 3 and 4 suggests a dynamic but still maturing clinical pipeline for HCC.

623 active
/
1396 total (since 2008)
219
Phase 1 Active
525 total
392
Phase 2 Active
850 total
93
Phase 3 Active
215 total
25
Phase 4 Active
58 total

Top Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 12 2 1
Roche 6 10 1
Akeso 6 5 0
Shanghai Henlius Biotech 4 0 1
AbbVie 4 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT03017326 ACTIVE NOT RECRUITING
Paediatric Hepatic International Tumour Trial
University of Birmingham n=450
NCT06921785 RECRUITING
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
AstraZeneca n=1,220
NCT03186898 ACTIVE NOT RECRUITING
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology n=186
NCT07166406 RECRUITING
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology n=226
NCT06618664 RECRUITING
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=590

+ 210 more Phase 3 trials — see full database below

Hepatocellular Carcinoma — Trials Started by Year (last 10 years)

2016
55
2017
58
2018
67
2019
72
2020
69
2021
88
2022
99
2023
108
2024
127
2025
157
2026
90

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AstraZeneca
15
Roche
17
Akeso
11
Shanghai Henlius Biotech
5
AbbVie
4
Bristol-Myers Squibb
16
Lion TCR Pte. Ltd.
5
Exelixis
4
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
3
Zhejiang Haichang Biotech Co., Ltd.
3

Active Trials by Phase

Phase 1
219
Phase 2
392
Phase 3
93
Phase 4
25

Enrollment Size Distribution

1-50
710
51-200
413
201-500
118
501-1k
57
1k+
11

All Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 12 2 1
Roche 6 10 1
Akeso 6 5 0
Shanghai Henlius Biotech 4 0 1
AbbVie 4 0 0
Bristol-Myers Squibb 3 10 3
Lion TCR Pte. Ltd. 3 1 1
Exelixis 3 1 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 3 0 0
Zhejiang Haichang Biotech Co., Ltd. 3 0 0
Abbisko Therapeutics Co, Ltd 3 0 0
Nanjing Sanhome Pharmaceutical, Co., Ltd. 3 0 0
Jiangsu HengRui Medicine Co., Ltd. 2 7 1
Boston Scientific Corporation 2 0 2
Eureka Therapeutics Inc. 2 0 2
NCT03017326 ACTIVE NOT RECRUITING
Paediatric Hepatic International Tumour Trial
University of Birmingham n=450
NCT06921785 RECRUITING
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
AstraZeneca n=1,220
NCT03186898 ACTIVE NOT RECRUITING
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology n=186
NCT07166406 RECRUITING
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology n=226
NCT06618664 RECRUITING
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=590
NCT07322848 RECRUITING
DEB-TACE vs cTACE in HCC After TIPS
First Affiliated Hospital, Sun Yat-Sen University n=206
NCT05883644 ACTIVE NOT RECRUITING
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
AstraZeneca n=111
NCT04712643 ACTIVE NOT RECRUITING
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche n=342
NCT07537946 NOT YET RECRUITING
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital n=400
NCT07490262 RECRUITING
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. n=680
NCT03778957 ACTIVE NOT RECRUITING
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
AstraZeneca n=724
NCT06485466 RECRUITING
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Guohui Xu n=101
NCT07293468 RECRUITING
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Tuen Mun Hospital n=106
NCT05016245 ACTIVE NOT RECRUITING
MANDARIN (S6371)
Boston Scientific Corporation n=92
NCT05301842 ACTIVE NOT RECRUITING
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
AstraZeneca n=760
NCT04039607 ACTIVE NOT RECRUITING
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb n=732
NCT03298451 ACTIVE NOT RECRUITING
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
AstraZeneca n=1,324
NCT04102098 ACTIVE NOT RECRUITING
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Hoffmann-La Roche n=668
NCT07475026 NOT YET RECRUITING
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Tianjin Medical University Cancer Institute and Hospital n=198
NCT07461675 NOT YET RECRUITING
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland n=30
NCT03847428 ACTIVE NOT RECRUITING
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
AstraZeneca n=908
NCT07302919 RECRUITING
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
University Hospital, Basel, Switzerland n=152
NCT07417397 RECRUITING
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University n=442
NCT04770896 ACTIVE NOT RECRUITING
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Hoffmann-La Roche n=557
NCT07392866 NOT YET RECRUITING
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd. n=120
NCT06904170 RECRUITING
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
UNICANCER n=196
NCT07381660 NOT YET RECRUITING
SBRT Versus Surgical Resection for Small HCC
Sun Yat-sen University n=312
NCT05198609 ACTIVE NOT RECRUITING
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University n=214
NCT07356037 NOT YET RECRUITING
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd. n=68
NCT07300488 ACTIVE NOT RECRUITING
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
Xi'an Xintong Pharmaceutical Research Co.,Ltd. n=60
NCT05904886 ACTIVE NOT RECRUITING
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
Hoffmann-La Roche n=687
NCT07309419 NOT YET RECRUITING
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital n=222
NCT04639180 ACTIVE NOT RECRUITING
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd. n=687
NCT03533582 ACTIVE NOT RECRUITING
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group n=537
NCT05317819 RECRUITING
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group n=300
NCT07285850 RECRUITING
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Eastern Hepatobiliary Surgery Hospital n=20
NCT07267806 RECRUITING
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
Linhui Peng n=326
NCT04194775 ACTIVE NOT RECRUITING
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
CStone Pharmaceuticals n=534
NCT05320692 ACTIVE NOT RECRUITING
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd. n=423
NCT03755791 ACTIVE NOT RECRUITING
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Exelixis n=837
NCT04523493 ACTIVE NOT RECRUITING
Phase III Study of Toripalimab（JS001��� Combined With Lenvatinib for Advanced HCC
Shanghai Junshi Bioscience Co., Ltd. n=530
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT06172205 RECRUITING
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=262
NCT03383458 ACTIVE NOT RECRUITING
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Bristol-Myers Squibb n=545
NCT06007846 RECRUITING
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Inova Health Care Services n=12
NCT06644937 RECRUITING
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
Zhujiang Hospital n=30
NCT07186621 RECRUITING
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=286
NCT06680258 NOT YET RECRUITING
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics n=740
NCT06109272 RECRUITING
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie n=660
NCT06841172 RECRUITING
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Shandong Cancer Hospital and Institute n=132
NCT02523443 ACTIVE NOT RECRUITING
Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection
Memorial Sloan Kettering Cancer Center n=231
NCT07027436 NOT YET RECRUITING
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
Hamilton Health Sciences Corporation n=30
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05482516 RECRUITING
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University n=20
NCT06900543 RECRUITING
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
Chengdu New Radiomedicine Technology Co. LTD. n=108
NCT04521153 ACTIVE NOT RECRUITING
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital n=294
NCT05201404 RECRUITING
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Can-Fite BioPharma n=471
NCT06844357 RECRUITING
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd n=300
NCT05489289 RECRUITING
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Akeso n=570
NCT06371157 RECRUITING
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Akeso n=469
NCT03895359 RECRUITING
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=128
NCT06841185 NOT YET RECRUITING
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Shanghai Henlius Biotech n=656
NCT04344158 ACTIVE NOT RECRUITING
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=648
NCT06796803 NOT YET RECRUITING
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital n=398
NCT05557838 RECRUITING
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
AstraZeneca n=210
NCT06492395 RECRUITING
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Second Affiliated Hospital of Guangzhou Medical University n=178
NCT06779461 NOT YET RECRUITING
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
InnoBM Pharmaceuticals Co., Ltd. n=228
NCT04803994 RECRUITING
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=434
NCT05613478 RECRUITING
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University n=130
NCT06739317 NOT YET RECRUITING
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Sun Yat-sen University n=398
NCT05744219 RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Jon Unosson n=338
NCT06041477 RECRUITING
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Sun Yat-sen University n=540
NCT04868149 RECRUITING
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
The University of Hong Kong n=40
NCT05594927 RECRUITING
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Beijing Shenogen Biomedical Co., Ltd n=261
NCT06478108 RECRUITING
Interventional Software for Multi-immunotherapy of Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=60
NCT03949231 RECRUITING
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT06434753 RECRUITING
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Hospital Universitari Vall d'Hebron Research Institute n=300
NCT06089369 NOT YET RECRUITING
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Tongji Hospital n=360
NCT05738616 RECRUITING
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Wen Tianfu n=196
NCT06201065 RECRUITING
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University n=200
NCT06089382 NOT YET RECRUITING
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Tongji Hospital n=104
NCT05985798 RECRUITING
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University n=258
NCT05976568 NOT YET RECRUITING
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd. n=668
NCT05608200 RECRUITING
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University n=427
NCT05862337 RECRUITING
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=480
NCT05408221 RECRUITING
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
Shandong New Time Pharmaceutical Co., LTD n=576
NCT05718232 NOT YET RECRUITING
SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
Sun Yat-sen University n=136
NCT05476432 RECRUITING
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Sun Yat-sen University n=300
NCT05608213 RECRUITING
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Second Affiliated Hospital of Guangzhou Medical University n=187
NCT04595864 RECRUITING
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=40
NCT03368651 RECRUITING
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University n=230
NCT07594340 RECRUITING
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Binkui Li n=300
NCT07589244 RECRUITING
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Guangzhou Virotech Pharmaceutical Co., Ltd. n=66
NCT03867084 COMPLETED
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Merck Sharp & Dohme LLC n=959
NCT04246177 COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
Merck Sharp & Dohme LLC n=479
NCT02771405 COMPLETED
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
National Hepatology & Tropical Medicine Research Institute n=150
NCT02435953 COMPLETED
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma
Ming Zhao n=241
NCT04720716 COMPLETED
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd. n=344
NCT04777851 TERMINATED
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
Translational Research in Oncology n=45
NCT05665348 COMPLETED
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Federation Francophone de Cancerologie Digestive n=229
NCT01903694 COMPLETED
Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
Centre Hospitalier Universitaire Dijon n=474
NCT03713593 COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Merck Sharp & Dohme LLC n=794
NCT01730937 COMPLETED
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group n=193
NCT05153785 COMPLETED
Perioperative Intravenous Lidocaine in Liver Surgery
Lund University Hospital n=124
NCT05171166 TERMINATED
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University n=18
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT05033522 SUSPENDED
Immunotherapy for Advanced Liver Cancer
Mirror Biologics, Inc. n=150
NCT03412773 COMPLETED
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene n=684
NCT02799212 COMPLETED
Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma
Hospices Civils de Lyon n=179
NCT03062358 COMPLETED
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
Merck Sharp & Dohme LLC n=453
NCT04487067 COMPLETED
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Hoffmann-La Roche n=152
NCT04732286 TERMINATED
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche n=100
NCT02764801 COMPLETED
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University n=131
NCT04268888 SUSPENDED
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
The Clatterbridge Cancer Centre NHS Foundation Trust n=522
NCT04709380 TERMINATED
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=36
NCT02576509 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb n=743
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT01906216 COMPLETED
Sorafenib Chemoembolization Evaluation Controlled Trial
Air Force Military Medical University, China n=199
NCT03960008 TERMINATED
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
Lahey Clinic n=9
NCT02112656 COMPLETED
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Imunon n=554
NCT02856126 COMPLETED
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University n=214
NCT04047173 COMPLETED
RFA Versus SBRT for Recurrent Small HCC
Sun Yat-sen University n=166
NCT02109146 COMPLETED
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
Zhejiang University n=332
NCT00617981 COMPLETED
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon n=701
NCT02762266 TERMINATED
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
Stanford University n=13
NCT04103398 COMPLETED
TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma
Sun Yat-sen University n=162
NCT03764293 COMPLETED
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd. n=543
NCT02650271 COMPLETED
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Guangxi Medical University n=240
NCT02649153 COMPLETED
Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection
Guangxi Medical University n=240
NCT02329860 COMPLETED
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd. n=400
NCT01004978 COMPLETED
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI) n=235
NCT00716976 COMPLETED
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group n=131
NCT03434379 COMPLETED
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Hoffmann-La Roche n=558
NCT00658593 TERMINATED
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
NCIC Clinical Trials Group n=19
NCT00699816 COMPLETED
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
GC Cell Corporation n=230
NCT02973685 COMPLETED
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
Sun Yat-sen University n=315
NCT05564338 WITHDRAWN
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
NCT03236649 TERMINATED
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd n=89
NCT02438436 COMPLETED
Simo Decoction and Gum Chewing for Bowel Activity
Guangxi Medical University n=180
NCT02435433 COMPLETED
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Eli Lilly and Company n=399
NCT02702401 COMPLETED
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
Merck Sharp & Dohme LLC n=413
NCT04985136 TERMINATED
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Jiangsu HengRui Medicine Co., Ltd. n=1
NCT01015833 COMPLETED
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI) n=356
NCT01402908 TERMINATED
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Cellxpert Biotechnology Corp. n=520
NCT04465734 WITHDRAWN
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
NCT01761266 COMPLETED
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Limited n=954
NCT01164202 COMPLETED
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
Federation Francophone de Cancerologie Digestive n=78
NCT01387932 TERMINATED
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Merit Medical Systems, Inc. n=235
NCT01655693 COMPLETED
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Valerio Therapeutics n=397
NCT01908426 COMPLETED
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Exelixis n=707
NCT01887717 TERMINATED
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
Boston Scientific Corporation n=36
NCT01755767 COMPLETED
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Daiichi Sankyo n=383
NCT02851784 COMPLETED
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
Chinese PLA General Hospital n=40
NCT02460991 TERMINATED
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
Boston Scientific Corporation n=2
NCT03164382 COMPLETED
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University n=262
NCT02562755 COMPLETED
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
SillaJen, Inc. n=459
NCT04546802 WITHDRAWN
HepATocellular Cancer Hcv Therapy Study
Bayside Health
NCT01774344 COMPLETED
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Bayer n=573
NCT01075555 COMPLETED
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive n=323
NCT03990974 SUSPENDED
Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
Sun Yat-sen University n=458
NCT01438476 COMPLETED
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
M.D. Anderson Cancer Center n=178
NCT02867280 TERMINATED
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University n=154
NCT01833299 COMPLETED
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Sun Yat-sen University n=120
NCT02645981 COMPLETED
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=668
NCT04044651 WITHDRAWN
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Shi Ming
NCT02774187 COMPLETED
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University n=247
NCT00908752 COMPLETED
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Bristol-Myers Squibb n=734
NCT00825955 COMPLETED
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
Bristol-Myers Squibb n=587
NCT01287585 COMPLETED
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
Polaris Group n=636
NCT03059238 COMPLETED
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
Sun Yat-sen University n=213
NCT01465464 TERMINATED
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Taiho Pharmaceutical Co., Ltd. n=888
NCT02584556 WITHDRAWN
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Guangxi Medical University
NCT02527772 WITHDRAWN
Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
NCT02534337 WITHDRAWN
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
NCT02585479 WITHDRAWN
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Guangxi Medical University
NCT00901901 COMPLETED
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Bayer n=732
NCT03791918 WITHDRAWN
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
NCT03744247 WITHDRAWN
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Sun Yat-sen University
NCT01676194 TERMINATED
Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma
Rennes University Hospital n=7
NCT01259414 COMPLETED
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
Sun Yat-sen University n=812
NCT01229839 COMPLETED
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
Sun Yat-sen University n=668
NCT02220088 TERMINATED
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Sun Yat-sen University n=79
NCT03636620 COMPLETED
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
Fudan University n=110
NCT00692770 COMPLETED
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Bayer n=1,114
NCT02971696 COMPLETED
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
Ain Shams University n=55
NCT02149771 WITHDRAWN
Combination Treatment for Advanced Liver Cancer
Shanghai Zhongshan Hospital
NCT01829035 COMPLETED
A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
National Cancer Center, Korea n=339
NCT01932385 COMPLETED
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Qingdao Central Hospital n=86
NCT01265810 COMPLETED
Caphosol in Oral Mucositis Due to Targeted Therapy
Impaqtt Foundation n=64
NCT01596283 COMPLETED
Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
Memorial Sloan Kettering Cancer Center n=135
NCT02029157 COMPLETED
A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
Kyowa Kirin Co., Ltd. n=386
NCT01901692 COMPLETED
Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
Asan Medical Center n=90
NCT02829359 COMPLETED
Effects of Antiviral Therapy on HBV Reactivation
Guangxi Medical University n=200
NCT01405573 TERMINATED
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
National Cancer Institute, Naples n=35
NCT01804829 COMPLETED
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Biotest Pharmaceuticals Corporation n=80
NCT01313377 COMPLETED
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
UNICANCER n=190
NCT02319200 TERMINATED
Primary Prevention Hepatocellular Carcinoma by Metformin
Assistance Publique - Hôpitaux de Paris n=11
NCT00858871 COMPLETED
First Line Hepato Cellular Carcinoma (HCC)
Bristol-Myers Squibb n=1,714
NCT02788526 COMPLETED
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Sun Yat-sen University n=180
NCT01964001 COMPLETED
The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer
Taichung Veterans General Hospital n=71
NCT02004210 WITHDRAWN
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma
Seoul National University Hospital
NCT00769106 COMPLETED
Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer
Sun Yat-sen University n=200
NCT01749865 COMPLETED
CIK Treatment for HCC Patient Underwent Radical Resection
Sun Yat-sen University n=200
NCT00820339 COMPLETED
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
Eastern Hepatobiliary Surgery Hospital n=132
NCT00814242 COMPLETED
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
Eastern Hepatobiliary Surgery Hospital n=120
NCT00827554 COMPLETED
The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital n=100
NCT01140347 COMPLETED
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Eli Lilly and Company n=565
NCT01108705 TERMINATED
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
Bristol-Myers Squibb n=87
NCT00902343 COMPLETED
Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection
Memorial Sloan Kettering Cancer Center n=149
NCT01872988 TERMINATED
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Taichung Veterans General Hospital n=320
NCT02038296 COMPLETED
Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
Guangdong Provincial People's Hospital n=162
NCT00699374 TERMINATED
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer n=1,075
NCT01009593 TERMINATED
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott n=1,035
NCT01327521 WITHDRAWN
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Albert Koong
NCT01318200 WITHDRAWN
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
Accuray Incorporated

Full Hepatocellular Carcinoma Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only